Artificial Intelligence in Digital Pathology to Advance Cancer Immunotherapy.

Pingjun Chen, Jianjun Zhang, Jia Wu

Open access · greenAbstract read

In one paragraph

Article in 21st century pathology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it

0cells of the map it votes in

5citing papers in PubMed

0.7field-weighted citation impact, top 31% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

Artificial intelligence in immune checkpoint inhibitor research: A bibliometric analysis of the landscape.Human vaccines & immunotherapeutics · 2026
Article
Unraveling the molecular-pathological characteristics and cellular complexity of the tumor immune microenvironment in metastatic non-small cell lung cancer.Cell communication and signaling : CCS · 2025
Review
A Thorough Review of the Clinical Applications of Artificial Intelligence in Lung Cancer.Cancers · 2025
Review
The role of artificial intelligence in immune checkpoint inhibitor research: A bibliometric analysis.Human vaccines & immunotherapeutics · 2024
Article
Construction of a prognostic risk model for uveal melanoma based on immune-related long noncoding RNA.Medicine · 2024
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Pingjun ChenDepartments of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Jianjun ZhangThoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Jia WuDepartments of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

The University of Texas MD Anderson Cancer Center · US

Funding

QUANTITATIVE IMAGING BIOMARKERS OF TREATMENT RESPONSE AND PROGNOSIS IN BREAST CANCERR00CA218667 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WU, JIA · 2020 to 2022

$747k

NCI NIH HHS R00 CA218667

6 · The paper itself

Abstract

Immune-checkpoint inhibitors (ICIs) have revolutionized the treatment of many malignancies. For instance, in lung cancer, however, only 20

Indexed as

Artificial intelligenceDigital pathologyImmunotherapyMultiplex bioimaging

Identifiers

PMID36282981

PMCPMC9578679

OpenAlexW4307503291

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.